$1.52
1.30%
Nasdaq, Oct 09, 04:13 pm EDT. Closed.
ISIN
US58468P2065
Symbol
MNOV

MediciNova, Inc. Stock price

$1.52
-0.27 15.08% 1M
+0.10 7.04% 6M
+0.21 16.03% YTD
+0.30 24.08% 1Y
-0.49 24.38% 3Y
-2.08 57.78% 5Y
-5.63 78.74% 10Y
-9.43 86.12% 20Y
Nasdaq, Closing price Fri, Oct 09 2026
-0.02 1.30%
ISIN
US58468P2065
Symbol
MNOV
Industry

Is MediciNova, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,113 stocks worldwide.

Key metrics

Basic
Market capitalization
$74.8m
Enterprise Value
$49.4m
Net debt
positive
Cash
$25.4m
Shares outstanding
49.2m
Valuation
P/E
negative
P/S | estimate
81.3 | 142.4
EV/Sales | estimate
53.7 | 94.0
EV/FCF | ex SBC
negative | negative
P/B
2.0
Financial Health
Equity Ratio
91.2%
Return on Equity
-28.9%
ROCE
-31.6%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$520.0k | 56.5%
SBC as % of FCF
-
SBC Growth 1Y
-58.4%
Share Count Growth 1Y
0.4%
Shareholder Yield
-0.4%
Financials
Revenue | estimate
$920.0k | $525.3k
EBITDA
$-11.8m
EBIT
$-11.9m
Net Income
$-10.8m
Free Cash Flow | ex SBC
$-9.1m | $-9.6m
Growth
Revenue | estimate
607.7% | 28.1%
EBITDA
10.9%
EBIT
10.9%
Net Income
9.0%
Free Cash Flow
9.3%
Margin
Gross
37.7%
EBITDA
-1,285.3%
EBIT
-1,287.4%
Net
-1,168.2%
Free Cash Flow | ex SBC
-991.2% | -1,047.2%
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
0.8%
Employees
6
Rev per Employee
$70.0k

MediciNova, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a MediciNova, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a MediciNova, Inc. forecast:

Buy
89%
Hold
11%

Financial data from MediciNova, Inc.

Jun '26
+/-
%
0.92 0.92
608% 608%
100%
- Direct Costs 0.57 0.57
375% 375%
62%
0.35 0.35
1,650% 1,650%
38%
- Selling and Administrative Expenses 6.78 6.78
23% 23%
737%
- Research and Development Expense 5.42 5.42
9% 9%
589%
-12 -12
11% 11%
-1,286%
- Depreciation and Amortization 0.02 0.02
0% 0%
2%
EBIT (Operating Income) EBIT -12 -12
11% 11%
-1,288%
Net Profit -11 -11
9% 9%
-1,168%

In millions USD.

Don't miss a Thing! We will send you all news about MediciNova, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MediciNova, Inc. Stock News

Neutral
GlobeNewsWire
●
4 days ago
LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that management will participate in the Maxim Growth Summit taking place October 12-14, 2026, at the Hard Rock Hotel New York. Management will be avai...
Neutral
GlobeNewsWire
●
12 days ago
MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat
Neutral
GlobeNewsWire
●
16 days ago
LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of the last patient, last visit (LPLV) in the double-blind portion of COMBAT-ALS, a Phase 2b/3 clinical trial evaluating MN-166 (ibudilast) for ...
More MediciNova, Inc. News

Company Profile

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Head office United States
CEO Dr. Iwaki
Employees 6
Founded 2000
Website medicinova.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today